Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Capeox in Locally Advanced Rectal Cancer
NCT04620473Phase 2Withdrawn
- Sponsor
- Shanghai Minimally Invasive Surgery Center
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of anlotinib in rectal cancer, sponsored by Shanghai Minimally Invasive Surgery Center. Planned start Nov 2023; status: withdrawn.
02
Drugs
anlotinib
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04620473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620473.